- ►annals.org [PDF] RA DeFronzo - Annals of internal medicine, 1999 - Am Coll Physicians Type 2 diabetes mellitus is a chronic metabolic disorder that results from
defects in both insulin secretion and insulin action. An elevated rate of basal
hepatic glucose production in the presence of hyperinsulinemia is the pri- ... Cited by 784 - Related articles - BL Direct - All 14 versions
РА ДеФронзо - mediasphera.ru Сахарный диабет (СД) II типа — это
хроническое расстройство обмена веществ,
обусловленное нарушением секреции и ... Related articles
- ►pharmyaring.com [PDF] SE Inzucchi - Jama, 2002 - Am Med Assoc Context Care of patients with type 2 diabetes has been revolutionized throughout
the past several years—first, by the realization of the importance of tight
glycemic control in forestalling complications, and second, by the ... Cited by 601 - Related articles - BL Direct - All 18 versions
RA DeFronzo, AM Goodman… - New England Journal of Medicine, 1995 - content.nejm.org Results In protocol 1, at the end of the study the 143 patients in the metformin
group, as compared with the 146 patients in the placebo group, had lower mean
(±SE) fasting plasma glucose concentrations (189±5 vs. 244±6 mg per ... Cited by 440 - Related articles - All 7 versions
RC Turner, CA Cull, V Frighi, RR Holman… - Jama, 1999 - Am Med Assoc Context Treatment with diet alone, insulin, sulfonylurea, or metformin is known
to improve glycemia in patients with type 2 diabetes mellitus, but which
treatment most frequently attains target fasting plasma glucose (FPG) ... Cited by 859 - Related articles - BL Direct - All 14 versions
CJ Bailey, RC Turner - New England Journal of Medicine, 1996 - content.nejm.org Metformin (dimethylbiguanide) is an orally administered drug used to lower blood
glucose concentrations in patients with non-insulin-dependent diabetes mellitus
(NIDDM). 1 It improves insulin sensitivity and thus decreases the insulin ... Cited by 714 - Related articles - BL Direct - All 5 versions
- Free from Publisher R Moses, R Slobodniuk, S Boyages, S Colagiuri … - Diabetes Care, 1999 - Am Diabetes Assoc I n the US, there are 7 million people with diagnosed type 2 diabetes (1).
Within the first 10 years of diagnosis, mo re than half of all those with type 2
dia- betes take oral hypoglycemic agents (2). ... Between 1970 and 1995, ... Cited by 210 - Related articles - BL Direct - All 7 versions
- ►zhaoys.com [PDF] V Fonseca, J Rosenstock, R Patwardhan, A … - Jama, 2000 - Am Med Assoc Context Most antidiabetic agents target only 1 of several underlying causes of
diabetes. The complementary actions of the antidiabetic agents metformin
hydrochloride and rosiglitazone maleate may maintain optimal glycemic ... Cited by 519 - Related articles - BL Direct - All 8 versions
M Stumvoll, N Nurjhan, G Perriello, G Dailey, … - New England Journal of Medicine, 1995 - content.nejm.org Results Metformin treatment decreased the mean (±SD) glycosylated hemoglobin
value from 13.2±2.2 percent to 10.5±1.6 percent (P<0.001) and reduced fasting
plasma glucose concentrations from 220±41 to 155±28 mg per deciliter ... Cited by 461 - Related articles - All 6 versions
